AI-081 is a differentiated bispecific antibody with robust cooperative interactions between PD1 and VEGFDosing of first patient in BIPAVE-001 ...

Instil Bio is a clinical-stage biotech focusing on personalized immunotherapy. Check out my recommendation for TIL stock.

Citadel ended September with 91% fewer Palantir shares, despite the stock's eye-popping gains, after selling about 5.2 ...

Researchers report detailed structural and atomic information for glassy and liquid magnesium silicates, which are important ...

By blocking PD-L1 and VEGF, Biotheus’ drug combines the mechanisms of action of Keytruda and Roche’s Avastin, two of the most important cancer drugs of the past 20 years. Keytruda works by helping ...

In randomized phase III trials two anti-vascular endothelial growth factor (VEGF) approaches have yielded survival benefit in patients with metastatic cancer. In one approach, the addition of ...

Merck (NYSE:MRK) and LaNova Medicines announced Thursday an agreement under which the U.S. pharmaceutical giant is expected ...

The deal makes Merck the latest company to acquire a type of dual-pronged cancer immunotherapy that’s fast become a top target of drugmakers. These so-called bispecific therapies simultaneously home ...

Their studies, including samples from human patients, indicated that anti-VEGF therapies may actually contribute to a lack of vision improvement by triggering the overexpression of a second ...

The "Metastatic Triple-Negative Breast Cancer (mTNBC)- Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.This report provides comprehensive insights about 10+ ...

Cells such as myeloid cells and cancer-associated fibroblasts in the tumor microenvironment release other substances and enzymes that encourage the growth of disorganized and leaky blood vessels. 1,11 ...

Summit Therapeutics shows promising results in Phase III trials for ivonescimab as a potential treatment for advanced NSCLC.